Zobrazeno 1 - 10
of 4 156
pro vyhledávání: '"Van Etten RA"'
Autor:
Rodriguez J; Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States.; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States., Iniguez A; Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States.; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States., Jena N; Department of Medicine, University of California, Irvine, Irvine, United States., Tata P; Department of Medicine, University of California, Irvine, Irvine, United States., Liu ZY; Department of Medicine, University of California, Irvine, Irvine, United States., Lander AD; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States., Lowengrub J; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States.; Department of Mathematics, University of California, Irvine, Irvine, United States., Van Etten RA; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Department of Medicine, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.
Publikováno v:
ELife [Elife] 2023 Apr 28; Vol. 12. Date of Electronic Publication: 2023 Apr 28.
Autor:
Mughal TI; Tufts University School of Medicine, Boston, Massachusetts, USA.; University of Buckingham, Buckingham, UK., Pemmaraju N; MD Anderson Cancer Center, University of Texas, Houston, Texas, USA., Bejar R; University of California San Diego, La Jolla, California, USA., Gale RP; Imperial College, London, UK., Bose P; MD Anderson Cancer Center, University of Texas, Houston, Texas, USA., Kiladjian JJ; Hôpital Saint-Louis, Université de Paris, Inserm, Paris, France., Prchal J; Huntsman Cancer Center, Salt Lake City, Utah, USA., Royston D; John Radcliffe Hospital, University of Oxford, Oxford, UK., Pollyea D; University of Colorado School of Medicine, Aurora, Colorado, USA., Valent P; Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Brümmendorf TH; University Hospital RWTH, Aachen, Germany., Skorski T; Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA., Patnaik M; Mayo Clinic, Rochester, Minnesota, USA., Santini V; Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy., Fenaux P; Hospital St Louis, Assistance Publique Hôpitaux de Paris, Paris, France., Kucine N; Weill Cornell Medicine, New York, New York, USA., Verstovsek S; MD Anderson Cancer Center, University of Texas, Houston, Texas, USA., Mesa R; Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA., Barbui T; Fondazione per la Ricerca Ospedale Maggiore di Bergamo, Bergamo, Italy., Saglio G; University of Turin, Turin, Italy., Van Etten RA; Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
Publikováno v:
Hematological oncology [Hematol Oncol] 2022 Oct; Vol. 40 (4), pp. 491-504. Date of Electronic Publication: 2022 Apr 15.
Autor:
Lin N; The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina., Lin Y; The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouChina., Xu J; Helio Health, Inc.IrvineCaliforniaUSA., Liu D; Laboratory for Advanced Medicine, Inc.BeijingChina., Li D; Guangzhou Youze Biological Pharmaceutical Technology Company LtdGuangzhouGuangdong ProvinceChina., Meng H; The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina., Gallant MA; Helio Health, Inc.IrvineCaliforniaUSA., Kubota N; Department of Internal MedicineSimmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallasTexasUSA., Roy D; Helio Health, Inc.IrvineCaliforniaUSA., Li JS; Division of Computational BiomedicineDepartment of Biological ChemistrySchool of MedicineUniversity of CaliforniaIrvineCaliforniaUSA., Gorospe EC; Texas Gastro ResearchEl PasoTexasUSA., Sherman M; University Health NetworkTorontoOntarioCanada., Gish RG; Hepatitis B FoundationDoylestownPennsylvaniaUSA., Abou-Alfa GK; Memorial Sloan Kettering Cancer CenterNew YorkNew YorkUSA., Nguyen MH; Division of Gastroenterology and Hepatology and Department of Epidemiology and Population HealthStanford University Medical CenterStanfordCaliforniaUSA., Taggart DJ; Helio Health, Inc.IrvineCaliforniaUSA., Van Etten RA; Department of MedicineChao Family Comprehensive Cancer CenterUniversity of CaliforniaIrvineCaliforniaUSA., Hoshida Y; Department of Internal MedicineSimmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallasTexasUSA., Li W; Division of Computational BiomedicineDepartment of Biological ChemistrySchool of MedicineUniversity of CaliforniaIrvineCaliforniaUSA.
Publikováno v:
Hepatology communications [Hepatol Commun] 2022 Jul; Vol. 6 (7), pp. 1753-1763. Date of Electronic Publication: 2022 Mar 03.
Autor:
Jafari M; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA. mjafari@uci.edu., Juanson Arabit JG; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA., Courville R; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA., Kiani D; Department of Microbiology and Immunology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA., Chaston JM; Department of Plant and Wildlife Sciences, Brigham Young University, Provo, UT, USA., Nguyen CD; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA., Jena N; Department of Medicine, University of California, Irvine, Irvine, CA, USA., Liu ZY; Department of Medicine, University of California, Irvine, Irvine, CA, USA., Tata P; Department of Medicine, University of California, Irvine, Irvine, CA, USA., Van Etten RA; Department of Medicine, University of California, Irvine, Irvine, CA, USA.
Publikováno v:
Scientific reports [Sci Rep] 2022 Jun 22; Vol. 12 (1), pp. 10581. Date of Electronic Publication: 2022 Jun 22.
Publikováno v:
Gu, S; Sayad, A; Chan, G; Yang, W; Lu, Z; Virtanen, C; et al.(2018). SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia, 32(1), 203-213. doi: 10.1038/leu.2017.250. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3866t0t6
© 2018 Macmillan Publishers Limited. BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph+) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::a83709cbea09326a9456db5dab918499
http://www.escholarship.org/uc/item/3866t0t6
http://www.escholarship.org/uc/item/3866t0t6
Autor:
Mughal TI; Tufts University Medical Center, Boston, MA, USA; University of Buckingham Medical School, Buckingham. tariq.mughal@tufts.edu., Psaila B; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford., DeAngelo DJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Saglio G; Orbassano University Hospital, Turin., Van Etten RA; University of California Irvine, Irvine, CA., Radich JP; Frederick Hutchinson Cancer Research Center, Seattle, WA.
Publikováno v:
Haematologica [Haematologica] 2021 Jul 01; Vol. 106 (7), pp. 1787-1793. Date of Electronic Publication: 2021 Jul 01.
Autor:
Petersen, Max1,2,3 (AUTHOR), Dubielecka, Pat1,2,3 (AUTHOR) patrycja_dubielecka-szczerba@brown.edu
Publikováno v:
Cell Communication & Signaling. 10/1/2024, Vol. 22 Issue 1, p1-26. 26p.
Autor:
Mughal TI; Tufts University Medical Center, Boston, Massachusetts, USA., Pemmaraju N; MD Anderson Cancer Center, Houston, Texas, USA., Psaila B; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Radich J; Frederick Hutchinson Cancer Research Center, Seattle, Washington, USA., Bose P; MD Anderson Cancer Center, Houston, Texas, USA., Lion T; Childrens Cancer Research Institute, Vienna, Austria., Kiladjian JJ; Hôpital Saint-Louis, Université de Paris, Paris, France., Rampal R; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Jain T; Sidney Kimmel Cancer Center, John Hopkins Hospital, Baltimore, Maryland, USA., Verstovsek S; MD Anderson Cancer Center, Houston, Texas, USA., Yacoub A; Division of Hematologic Malignancies, University of Kansas, Kansas City, Kansas, USA., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia, USA., Mesa R; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA., Saglio G; Orbassano University Hospital, Turin, Italy., van Etten RA; University of California Irvine, Irvine, California, USA.
Publikováno v:
Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 654-664. Date of Electronic Publication: 2020 Sep 04.
Autor:
Kumar R; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Pereira RS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Zanetti C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Minciacchi VR; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Merten M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Meister M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Niemann J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Dietz MS; Institute for Physical and Theoretical Chemistry, Goethe-University Frankfurt, Frankfurt am Main, Germany., Rüssel N; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany., Schnütgen F; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany., Tamai M; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan., Akahane K; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan., Inukai T; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan., Oellerich T; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Kvasnicka HM; Senckenberg Institute of Pathology, Goethe University Frankfurt, 60590, Frankfurt am Main, Germany., Pfeifer H; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany., Nicolini FE; Department of Hematology and INSERM U 1052, CRCL, Centre Léon Bérard, 69373, Lyon Cedex, France., Heilemann M; Institute for Physical and Theoretical Chemistry, Goethe-University Frankfurt, Frankfurt am Main, Germany., Van Etten RA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, 92697, USA., Krause DS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany. Krause@gsh.uni-frankfurt.de.; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany. Krause@gsh.uni-frankfurt.de.; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany. Krause@gsh.uni-frankfurt.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. Krause@gsh.uni-frankfurt.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. Krause@gsh.uni-frankfurt.de.
Publikováno v:
Leukemia [Leukemia] 2020 Aug; Vol. 34 (8), pp. 2087-2101. Date of Electronic Publication: 2020 May 21.
Publikováno v:
Roumiantsev, S; de Aos, IE; Varticovski, L; Ilaria, RL; & Van Etten, RA. (2001). The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.. Blood, 97(1), 4-13. doi: 10.1182/blood.v97.1.4. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/37b6b07f
The effect of mutations in the Src homology 2 (SH2) domain of the BCR/ABL oncogene on leukemogenesis was tested in a quantitative murine bone marrow transduction/transplantation assay that accurately models human Philadelphia-positive B-lymphoid leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::6a7220e39778c6df0309707fe9739c54
http://www.escholarship.org/uc/item/37b6b07f
http://www.escholarship.org/uc/item/37b6b07f